In this regard, we have to also consider that by stopping the EGFR-TKI treatment due to the progression of the disease, there is a risk of a rebound tumor flare, which can occur in about 20% of the patients, and may play a role in treatment choice. The gene discussed is EGFR; the disease is neoplasm.